Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS7609)

• Drug Name: YM-358 Drug Info
• Synonyms: 2,7-Diethyl-5-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-5H-pyrazolo[1,5-b][1,2,4]triazole potassium salt monohydrate

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 9801006
  TTD Drug ID: DMS7609

Molecule-Related Drug Atlas

Drug(s) Targeting Angiotensin II receptor type-1 (AGTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Losartan	DM72JXH	Diabetic kidney disease	GB61.Z	Approved	[3]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[4]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[3]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[3]
Candesartan	DMRK8OT	Chronic heart failure	BD1Z	Approved	[5]
Telmisartan	DMS3GX2	Hypertension	BA00-BA04	Approved	[6]
ANGIOTENSIN II	DMLWQ27	Increase blood pressure	BA04	Approved	[7]
SARALASIN	DMKS1DV	Hypertension	BA00-BA04	Approved	[8]
Tasosartan	DMM13DI	Hypertension	BA00-BA04	Approved	[9]
Eprosartan	DM07K2I	Hypertension	BA00-BA04	Approved	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin II receptor type-1 (AGTR1)	TT8DBY3	AGTR1_HUMAN	Antagonist	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002583)
• [2] Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81.
• [3] Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
• [4] Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
• [5] Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
• [6] Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
• [7] The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
• [8] Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
• [9] Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
• [10] Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.